A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome

Immunological analysis of B cells, T cells and cytokines

Y. Tamimoto, Takahiko Horiuchi, H. Tsukamoto, J. Otsuka, Hiroki Mitoma, yasutaka kimoto, H. Nakashima, K. Muta, Y. Abe, Chikako Kiyohara, A. Ueda, K. Nagasawa, S. Yoshizawa, T. Shimoda, M. Harada

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective. Accumulating evidence suggests that B-cell depletion therapy by rituximab may be effective for autoimmune disorders. However, an optimal dose of rituximab and a mechanism of its action remain to be established. We performed a dose-escalation study for treatment of Japanese patients with autoimmune diseases including eight with SLE and one with Evans' syndrome. Methods. Rituximab was infused intravenously, weekly 4 times in a dose-escalating fashion at three different doses of 100, 250 or 375 mg/m 2 to three patients each. Immunological parameters were monitored at certain points until 12 months after the treatment. Results. Rituximab was well tolerated and safe in these patients. Seven out of eight SLE patients and one with Evans' syndrome clinically responded completely or partially to the treatment. Four patients achieved long-term remission (18-30 months) without any additional treatment. In these patients, a significant decrease in circulating B cells continued for 6 months after the treatment. The mean fluorescence intensities of CD19, CD21, CD40 and BR3 on the residual B cells as well as the percentage of CD69+ CD4+ T cells decreased significantly. Serum TNF-α levels decreased significantly on day 2. The Th1/Th2 balance of CD4+ T cells gradually shifted towards a Th1 type by 6 months. Conclusion. In addition to B-cell depletion, modification of B-cell and T-cell phenotypes as well as cytokine profiles may be involved in the action of rituximab.

Original languageEnglish
Pages (from-to)821-827
Number of pages7
JournalRheumatology
Volume47
Issue number6
DOIs
Publication statusPublished - Jun 1 2008

Fingerprint

Systemic Lupus Erythematosus
B-Lymphocytes
Cytokines
T-Lymphocytes
Therapeutics
Th1-Th2 Balance
Cell- and Tissue-Based Therapy
Autoimmune Diseases
Evans Syndrome
Rituximab
Fluorescence
Phenotype
Serum

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Pharmacology (medical)

Cite this

A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome : Immunological analysis of B cells, T cells and cytokines. / Tamimoto, Y.; Horiuchi, Takahiko; Tsukamoto, H.; Otsuka, J.; Mitoma, Hiroki; kimoto, yasutaka; Nakashima, H.; Muta, K.; Abe, Y.; Kiyohara, Chikako; Ueda, A.; Nagasawa, K.; Yoshizawa, S.; Shimoda, T.; Harada, M.

In: Rheumatology, Vol. 47, No. 6, 01.06.2008, p. 821-827.

Research output: Contribution to journalArticle

Tamimoto, Y. ; Horiuchi, Takahiko ; Tsukamoto, H. ; Otsuka, J. ; Mitoma, Hiroki ; kimoto, yasutaka ; Nakashima, H. ; Muta, K. ; Abe, Y. ; Kiyohara, Chikako ; Ueda, A. ; Nagasawa, K. ; Yoshizawa, S. ; Shimoda, T. ; Harada, M. / A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome : Immunological analysis of B cells, T cells and cytokines. In: Rheumatology. 2008 ; Vol. 47, No. 6. pp. 821-827.
@article{9ffe2b628f4b4a2abf035703030f1ab8,
title = "A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: Immunological analysis of B cells, T cells and cytokines",
abstract = "Objective. Accumulating evidence suggests that B-cell depletion therapy by rituximab may be effective for autoimmune disorders. However, an optimal dose of rituximab and a mechanism of its action remain to be established. We performed a dose-escalation study for treatment of Japanese patients with autoimmune diseases including eight with SLE and one with Evans' syndrome. Methods. Rituximab was infused intravenously, weekly 4 times in a dose-escalating fashion at three different doses of 100, 250 or 375 mg/m 2 to three patients each. Immunological parameters were monitored at certain points until 12 months after the treatment. Results. Rituximab was well tolerated and safe in these patients. Seven out of eight SLE patients and one with Evans' syndrome clinically responded completely or partially to the treatment. Four patients achieved long-term remission (18-30 months) without any additional treatment. In these patients, a significant decrease in circulating B cells continued for 6 months after the treatment. The mean fluorescence intensities of CD19, CD21, CD40 and BR3 on the residual B cells as well as the percentage of CD69+ CD4+ T cells decreased significantly. Serum TNF-α levels decreased significantly on day 2. The Th1/Th2 balance of CD4+ T cells gradually shifted towards a Th1 type by 6 months. Conclusion. In addition to B-cell depletion, modification of B-cell and T-cell phenotypes as well as cytokine profiles may be involved in the action of rituximab.",
author = "Y. Tamimoto and Takahiko Horiuchi and H. Tsukamoto and J. Otsuka and Hiroki Mitoma and yasutaka kimoto and H. Nakashima and K. Muta and Y. Abe and Chikako Kiyohara and A. Ueda and K. Nagasawa and S. Yoshizawa and T. Shimoda and M. Harada",
year = "2008",
month = "6",
day = "1",
doi = "10.1093/rheumatology/ken071",
language = "English",
volume = "47",
pages = "821--827",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome

T2 - Immunological analysis of B cells, T cells and cytokines

AU - Tamimoto, Y.

AU - Horiuchi, Takahiko

AU - Tsukamoto, H.

AU - Otsuka, J.

AU - Mitoma, Hiroki

AU - kimoto, yasutaka

AU - Nakashima, H.

AU - Muta, K.

AU - Abe, Y.

AU - Kiyohara, Chikako

AU - Ueda, A.

AU - Nagasawa, K.

AU - Yoshizawa, S.

AU - Shimoda, T.

AU - Harada, M.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Objective. Accumulating evidence suggests that B-cell depletion therapy by rituximab may be effective for autoimmune disorders. However, an optimal dose of rituximab and a mechanism of its action remain to be established. We performed a dose-escalation study for treatment of Japanese patients with autoimmune diseases including eight with SLE and one with Evans' syndrome. Methods. Rituximab was infused intravenously, weekly 4 times in a dose-escalating fashion at three different doses of 100, 250 or 375 mg/m 2 to three patients each. Immunological parameters were monitored at certain points until 12 months after the treatment. Results. Rituximab was well tolerated and safe in these patients. Seven out of eight SLE patients and one with Evans' syndrome clinically responded completely or partially to the treatment. Four patients achieved long-term remission (18-30 months) without any additional treatment. In these patients, a significant decrease in circulating B cells continued for 6 months after the treatment. The mean fluorescence intensities of CD19, CD21, CD40 and BR3 on the residual B cells as well as the percentage of CD69+ CD4+ T cells decreased significantly. Serum TNF-α levels decreased significantly on day 2. The Th1/Th2 balance of CD4+ T cells gradually shifted towards a Th1 type by 6 months. Conclusion. In addition to B-cell depletion, modification of B-cell and T-cell phenotypes as well as cytokine profiles may be involved in the action of rituximab.

AB - Objective. Accumulating evidence suggests that B-cell depletion therapy by rituximab may be effective for autoimmune disorders. However, an optimal dose of rituximab and a mechanism of its action remain to be established. We performed a dose-escalation study for treatment of Japanese patients with autoimmune diseases including eight with SLE and one with Evans' syndrome. Methods. Rituximab was infused intravenously, weekly 4 times in a dose-escalating fashion at three different doses of 100, 250 or 375 mg/m 2 to three patients each. Immunological parameters were monitored at certain points until 12 months after the treatment. Results. Rituximab was well tolerated and safe in these patients. Seven out of eight SLE patients and one with Evans' syndrome clinically responded completely or partially to the treatment. Four patients achieved long-term remission (18-30 months) without any additional treatment. In these patients, a significant decrease in circulating B cells continued for 6 months after the treatment. The mean fluorescence intensities of CD19, CD21, CD40 and BR3 on the residual B cells as well as the percentage of CD69+ CD4+ T cells decreased significantly. Serum TNF-α levels decreased significantly on day 2. The Th1/Th2 balance of CD4+ T cells gradually shifted towards a Th1 type by 6 months. Conclusion. In addition to B-cell depletion, modification of B-cell and T-cell phenotypes as well as cytokine profiles may be involved in the action of rituximab.

UR - http://www.scopus.com/inward/record.url?scp=44849100527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849100527&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ken071

DO - 10.1093/rheumatology/ken071

M3 - Article

VL - 47

SP - 821

EP - 827

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 6

ER -